MINERALYS THERAPEUTICS, INC. Accrued Liabilities, Current
MINERALYS THERAPEUTICS, INC. (MLYS) had Accrued Liabilities, Current of $18.25 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Accrued Liabilities, Current $18.25M.
- 2026-03-31: Accrued Liabilities, Current $13.60M.
- 2025-12-31: Accrued Liabilities, Current $13.10M.
- 2025-09-30: Accrued Liabilities, Current $22.40M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $18.25M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $13.60M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $13.10M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $22.40M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $19.01M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $13.01M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $14.17M 10-K · filed 2026-03-12 |
| 2024-09-30 | $28.21M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $26.69M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $14.94M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $9.88M 10-K · filed 2025-02-12 |
| 2023-09-30 | $7.97M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $4.01M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $8.17M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $6.16M 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |